Ayse Okan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Ayse Okan has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Önder Ergönül
Department of Infectious Diseases and Clinical Microbiology, Koç University School of Medicine, Istanbul, Türkiye
2 shared publications - Aydın Çelikyurt
Department of Pediatrics, Faculty of Medicine, Erciyes University, Kayseri, Turkey
1 shared publication - Berk Mizrak
Department of medicine Koç University School of Medicine İstanbul Turkey
1 shared publication - Berna Ozer
Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
1 shared publication - Cansel Vatansever
Koc University
1 shared publication - Cansin Sackesen
Division of Pediatric Allergy, Koc University School of Medicine, Istanbul, Türkiye
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Springer Nature in BMC Infectious Diseases
Predictors and mortality in PCR-positive pneumocystis pneumonia among non-HIV patients
Pneumocystis jirovecii is a major cause of morbidity and mortality in HIV. It also poses a significant risk to non-HIV immunocompromised patients, especially those with cancer or recent chemotherapy. We evaluated risk factors, diagnostic markers-including lactate dehydrogenase (LDH)-and mortality predictors in PCR-confirmed pneumocystis pneumonia (PJP). We retrospectively analyzed patients with hypoxemia, pulmonary involvement and/or fever who underwent PJP PCR testing at Koç University Hospital between January 2020 and November 2023. Cases were defined as patients with a positive PCR result who fulfilled the EORTC/MSGERC criteria for PJP, whereas the non-PJP group included PCR-negative patients and PCR-positive patients without clinically compatible disease. Clinical, laboratory, and radiologic data-including LDH, fungal load, co-infections, and 4-week mortality-were collected. Of 235 patients, 59 had PCR-confirmed PJP. PJP patients were older (median 70 vs. 64.5, p < 0.001), more often had solid organ malignancies (67.8% vs. 41.5%, p < 0.001), recent chemotherapy (66.1% vs. 41.5%, p = 0.001), and higher fungal loads (median 10,892 vs. 0, p < 0.001). Bilateral lung lesions (81% vs. 66.5%, p = 0.037) and ground-glass opacities (82.8% vs. 67.7%, p = 0.041) were more frequent. Serum LDH increased by 81.6% in PJP vs. 20.7% in controls (p = 0.001), whereas no significant difference was observed among patients with elevated baseline LDH (29.7% vs. 16.3%, p = 0.397). Multivariate analysis identified older age (OR 1.042, p = 0.017), solid organ malignancy (OR 2.304, p = 0.048), and CMV co-infection (OR 3.786, p = 0.006) as independent factors associated with PJP, whereas ICU admission at diagnosis was inversely associated with PJP (OR 0.239, p = 0.005). The 4-week mortality was 37%, with bacterial co-infection as the strongest predictor (OR 5.854, p = 0.009). Older age, solid organ malignancy, and CMV co-infection increased PJP risk, while bacterial co-infection predicted mortality. LDH changes supported diagnosis, but not when baseline levels were already elevated, in this predominantly oncology cohort.
- 30 June 2026
- Published by Springer Nature in BMC Infectious Diseases
Open AccessPredictors and mortality in PCR-positive pneumocystis pneumonia among non-HIV patients
Pneumocystis jirovecii is a major cause of morbidity and mortality in HIV. It also poses a significant risk to non-HIV immunocompromised patients, especially those with cancer or recent chemotherapy. We evaluated risk factors, diagnostic markers-including lactate dehydrogenase (LDH)-and mortality predictors in PCR-confirmed pneumocystis pneumonia (PJP). We retrospectively analyzed patients with hypoxemia, pulmonary involvement and/or fever who underwent PJP PCR testing at Koç University Hospital between January 2020 and November 2023. Cases were defined as patients with a positive PCR result who fulfilled the EORTC/MSGERC criteria for PJP, whereas the non-PJP group included PCR-negative patients and PCR-positive patients without clinically compatible disease. Clinical, laboratory, and radiologic data-including LDH, fungal load, co-infections, and 4-week mortality-were collected. Of 235 patients, 59 had PCR-confirmed PJP. PJP patients were older (median 70 vs. 64.5, p < 0.001), more often had solid organ malignancies (67.8% vs. 41.5%, p < 0.001), recent chemotherapy (66.1% vs. 41.5%, p = 0.001), and higher fungal loads (median 10,892 vs. 0, p < 0.001). Bilateral lung lesions (81% vs. 66.5%, p = 0.037) and ground-glass opacities (82.8% vs. 67.7%, p = 0.041) were more frequent. Serum LDH increased by 81.6% in PJP vs. 20.7% in controls (p = 0.001), whereas no significant difference was observed among patients with elevated baseline LDH (29.7% vs. 16.3%, p = 0.397). Multivariate analysis identified older age (OR 1.042, p = 0.017), solid organ malignancy (OR 2.304, p = 0.048), and CMV co-infection (OR 3.786, p = 0.006) as independent factors associated with PJP, whereas ICU admission at diagnosis was inversely associated with PJP (OR 0.239, p = 0.005). The 4-week mortality was 37%, with bacterial co-infection as the strongest predictor (OR 5.854, p = 0.009). Older age, solid organ malignancy, and CMV co-infection increased PJP risk, while bacterial co-infection predicted mortality. LDH changes supported diagnosis, but not when baseline levels were already elevated, in this predominantly oncology cohort.
- 31 August 2021
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 3 (2) , 78-86
Infectivity of Adult and Pediatric COVID-19 Patients
The clinical findings of SARS-CoV-2 infection are heterogeneous, and the duration of viral RNA shedding varies on the age of the patient, severity of the disease, and type of the sample. For that reason, a comprehensive analysis of the dynamics of viral shedding is critical for (...)
- 31 August 2021
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 3 (2) , 78-86
Infectivity of Adult and Pediatric COVID-19 Patients
The clinical findings of SARS-CoV-2 infection are heterogeneous, and the duration of viral RNA shedding varies on the age of the patient, severity of the disease, and type of the sample. For that reason, a comprehensive analysis of the dynamics of viral shedding is critical for (...)